Journal: Frontiers in Pharmacology
Article Title: Hemoglobin α-derived peptides VD-hemopressin (α) and RVD-hemopressin (α) are involved in electroacupuncture inhibition of chronic pain
doi: 10.3389/fphar.2024.1439448
Figure Lengend Snippet: Effects of the 26S proteasome inhibitor MG132 on EA analgesia and RVD-hemopressin (α) concentration in the PAG. (A, B) Time course of the effect of the 26S proteasome inhibitor MG132 on tactile and thermal withdrawal thresholds of EA mice. EA was administered for 30 min, once every other day for 4 weeks, starting from 2 days after the MIA injection. The 26S proteasome inhibitor MG132 (4 μg) was microinjected into the vlPAG 30 min before EA starting from 18 days after MIA injection, once every other day for five times, as indicated by the black arrow. Data are expressed as means ± SEM (n = 8–11 mice in each group). * p < 0.05, compared with the KOA group; # p < 0.05, compared with the 10% DMSO + EA group. (C) Summary data show the concentration of RVD-hemopressin (α) in the PAG. Data are expressed as means ± SEM (n = 4–6 mice in each group). * p < 0.001.
Article Snippet: MG132 (Z-Leu-Leu-Leu-al), a 26S proteasome inhibitor (Merck Millipore, United States) and AM251, a CB1 receptor selective antagonist (MCE, United States) were dissolved in the 10% dimethyl sulfoxide (10% DMSO; Sigma-Aldrich).
Techniques: Concentration Assay, Injection